| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse e... |
| 06 Oct 2026 |
Form 4: Bowen Matthew, Principal Accounting Officer
Sold 13 shares ($137) |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Degrading Proteins, Making Medicines MRT-8102 GFORCE-1 Clinical Study Results October 1, 2026 Exhibit 99.2 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 |
| 17 Jul 2026 |
Form 4: Warmuth Markus, Director
Sold 9,500 shares ($220K) |
| 16 Jul 2026 |
Form 4: Champoux Jennifer, Chief Operating Officer
Received 4,351 shares by exercise or conversion ($17.3K) · Sold 4,351 shares ($102K) |
| 16 Jul 2026 | 144 |
| 15 Jul 2026 | 144 |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 07 Jul 2026 |
Form 4: Townson Sharon, Chief Scientific Officer
Received 6,000 shares by exercise or conversion ($36.8K) · Sold 6,000 shares ($140K) |
| 06 Jul 2026 |
Form 4: Behbahani Ali, Director
Disposed of 1,015,000 shares (Other Transaction) · Acquired 15,000 shares (Other Transaction) |
Loading...